Terra Innovatum Releases Updated Investor Presentation Highlighting Continued Progress Across Regulatory, Manufacturing, And Commercial Initiatives; Terra Targets FOAK Deployment Beginning In 2027 With Commercialization In 2028

Advancing regulatory pathway, fully secured supply chain, and growing commercial traction position the Company for scalable deployment across AI, industrial, and healthcare markets NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Terra Innovatum Global N.V. (NASDAQ:NKLR) ("Terra Innovatum" or the "Company"), developer of the SOLO™ Micro-Modular Reactor, today announced the release of an updated investor presentation highlighting continued progress across regulatory, manufacturing, and commercial initiatives, as well as an expanded set of high-value end-market opportunities.The updated presentation will be featured in connection with Terra Innovatum's participation at the ROTH Conference, where management is presenting, participating in panel discussions, and hosting one-on-one investor meetings.The updated materials underscore several important developments:Advanced Regulatory Progress and Clear Licensing PathwayTerra continues to advance its engagement with the U.S. Nuclear Regulatory Commission (NRC), with multiple technical submissions completed and the pre-application phase nearing completion, supporting readiness for Construction Permit Application (CPA) submissionDesign Completion and Fully Funded Path to First DeploymentThe SOLO™ reactor design is complete, with no further R&D expected for first-of-a-kind (FOAK) deployment or next-of-a-kind (NOAK) commercialization, and existing capital expected to fully fund licensing, construction, and initial operationsEnd-to-End Supply Chain Secured and Manufacturing UnderwayTerra has secured a full nuclear-grade supply chain and initiated pre-fabrication and manufacturing activities, significantly de-risking deployment timelines and enabling scalable production Scalable, Asset-Light "Fabless" Manufacturing ModelThe Company's factory-based, partner-driven production strategy is expected to support rapid scaling from hundreds to potentially thousands of units annually over time Expanding Commercial Traction Across High-Growth End MarketsTerra is seeing strong demand across data centers, industrial applications, infrastructure, and healthcare, with approximately 200 non-binding pre-commercial unit commitments representing ~$4 billion in potential value Strategic Positioning in AI Infrastructure and Other Key Energy-Constrained MarketsRecent commercial initiatives include a pilot deployment supporting next-generation AI data centers, with potential to scale significantly as demand for reliable, behind-the-meter power accelerates Introduction of High-Value Product Extensions, Including RadioisotopesThe updated materials highlight SOLO's ability to produce multiple outputs — including electricity, process heat, and radioisotopes — expanding the Company's addressable market into high-margin healthcare and advanced industrial applications Clear Path from FOAK to Commercial Scale DeploymentTerra is targeting FOAK deployment beginning in 2027 with commercialization in 2028, supported by a streamlined licensing approach and standardized reactor design